Header Logo

Connection

James Mulshine to Male

This is a "connection" page, showing publications James Mulshine has written about Male.
Connection Strength

0.415
  1. One Screening for Ischemic Heart Disease, Lung Cancer, and Chronic Obstructive Pulmonary Disease: A Systems Biology Bridge for Tobacco and Radiation Exposure. Am J Public Health. 2018 10; 108(10):1294-1295.
    View in: PubMed
    Score: 0.050
  2. Lung Cancer Workshop XI: Tobacco-Induced Disease: Advances in Policy, Early Detection and Management. J Thorac Oncol. 2015 May; 10(5):762-767.
    View in: PubMed
    Score: 0.040
  3. Lung cancer screening with low-dose CT: more questions than answers--author's reply. Lancet Oncol. 2015 Jan; 16(1):e4.
    View in: PubMed
    Score: 0.039
  4. Lung cancer screening: achieving more by intervening less. Lancet Oncol. 2014 Nov; 15(12):1284-5.
    View in: PubMed
    Score: 0.038
  5. Not significant but important. Cancer Prev Res (Phila). 2013 May; 6(5):371-4.
    View in: PubMed
    Score: 0.035
  6. A quantitative method for estimating individual lung cancer risk. Acad Radiol. 2010 Jul; 17(7):830-40.
    View in: PubMed
    Score: 0.028
  7. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res. 2004 Mar 01; 10(5):1565-73.
    View in: PubMed
    Score: 0.018
  8. Surgical considerations with lung cancer screening. J Surg Oncol. 2003 Sep; 84(1):1-6.
    View in: PubMed
    Score: 0.018
  9. Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res. 2000 Aug; 6(8):3015-24.
    View in: PubMed
    Score: 0.014
  10. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3385-93.
    View in: PubMed
    Score: 0.014
  11. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 1999 May 01; 59(9):2223-8.
    View in: PubMed
    Score: 0.013
  12. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene. 1994 Sep; 9(9):2441-8.
    View in: PubMed
    Score: 0.009
  13. Growth factors and other targets for rational application as intervention agents. Adv Exp Med Biol. 1992; 320:81-8.
    View in: PubMed
    Score: 0.008
  14. Direct intralymphatic injection of radiolabeled 111In-T101 in patients with cutaneous T-cell lymphoma. Cancer Res. 1991 Jan 15; 51(2):688-95.
    View in: PubMed
    Score: 0.007
  15. A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity. Am J Clin Oncol. 1990 Aug; 13(4):285-9.
    View in: PubMed
    Score: 0.007
  16. An actuarial approach to comparing early stage and late stage lung cancer mortality and survival. Popul Health Manag. 2010 Feb; 13(1):33-46.
    View in: PubMed
    Score: 0.007
  17. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J Clin Oncol. 1988 Nov; 6(11):1685-93.
    View in: PubMed
    Score: 0.006
  18. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer. 2008 Sep; 61(3):340-9.
    View in: PubMed
    Score: 0.006
  19. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6.
    View in: PubMed
    Score: 0.006
  20. Clinical significance of the association of the Von Hippel-Lindau disease with pheochromocytoma and pancreatic apudoma. Am J Med Sci. 1984 Dec; 288(5):212-6.
    View in: PubMed
    Score: 0.005
  21. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. J Clin Oncol. 1984 Jul; 2(7):733-41.
    View in: PubMed
    Score: 0.005
  22. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung Cancer. 2001 Dec; 34(3):341-50.
    View in: PubMed
    Score: 0.004
  23. Topical delivery of 13-cis-retinoic acid by inhalation up-regulates expression of rodent lung but not liver retinoic acid receptors. Clin Cancer Res. 2000 Sep; 6(9):3636-45.
    View in: PubMed
    Score: 0.004
  24. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate. 1998 Nov 01; 37(3):161-73.
    View in: PubMed
    Score: 0.003
  25. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2237-46.
    View in: PubMed
    Score: 0.003
  26. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 1997 Jul; 112(1):256-61.
    View in: PubMed
    Score: 0.003
  27. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996 Mar; 14(3):806-13.
    View in: PubMed
    Score: 0.003
  28. Expression of early lung cancer detection marker p31 in neoplastic and non-neoplastic respiratory epithelium. Lung Cancer. 1996 Feb; 14(1):85-97.
    View in: PubMed
    Score: 0.003
  29. The early detection of second primary lung cancers by sputum immunostaining. LCEWDG Investigators. Lung Cancer Early Detection Group. Chest. 1994 Dec; 106(6 Suppl):385S-390S.
    View in: PubMed
    Score: 0.002
  30. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct; 12(10):2022-34.
    View in: PubMed
    Score: 0.002
  31. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 1994 May 01; 54(9):2496-503.
    View in: PubMed
    Score: 0.002
  32. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992 Jun; 53(6):992-8.
    View in: PubMed
    Score: 0.002
  33. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 1992 Jan; 7(1):171-80.
    View in: PubMed
    Score: 0.002
  34. Expression of surfactant-associated protein in non-small-cell lung cancer: a discriminant between biologic subsets. J Natl Cancer Inst Monogr. 1992; (13):61-6.
    View in: PubMed
    Score: 0.002
  35. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991 Aug; 6(8):1353-62.
    View in: PubMed
    Score: 0.002
  36. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol. 1990 Jun; 8(6):1042-9.
    View in: PubMed
    Score: 0.002
  37. Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody. J Nucl Med. 1987 Jan; 28(1):42-6.
    View in: PubMed
    Score: 0.001
  38. Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med. 1986 Sep 11; 315(11):673-80.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.